Distribution and Fractionation of Uranium in Weapon Tested Range Soils.

Uranium is a chemically toxic and radioactive heavy metal. Depleted uranium (DU) is the byproduct of the uranium enrichment process, with a majority of U as uranium-238, and a lower content of the fissile isotope uranium-235 than natural uranium. Uranium-235 is mainly used in nuclear reactors and in the manufacture of nuclear weapons. Exposure is likely to have an impact on humans or the ecosystem where military operations have used DU. Yuma Proving Ground in Arizona, USA has been using depleted uranium ballistics for 36 years. At a contaminated site in the Proving Grounds, soil samples were collected from the flat, open field and lower elevated trenches that typically collect summer runoff. Spatial distribution and fractionation of uranium in the fields were analyzed with total acid digestion and selective sequential dissolution with eight operationally defined solid-phase fractions. In addition to uranium, other trace elements (As, Ba, Co, Cr, Cu, Hg, Mo, Nb, Pd, Pb, V, Zn, Zr) were also assessed. Results show that the trench area in the testing site had a higher accumulation of total U (12.4%) compared to the open-field soil with 279 mg/kg U. Among the eight solid-phase components in the open-field samples, U demonstrated stronger affinities for the amorphous iron-oxide bound, followed by the carbonate bound, and the residual fractions. However, U in the trench area had a stronger binding to the easily reducible oxide bound fraction, followed by the carbonate-bound and amorphous iron-oxide-bound fractions. Among other trace elements, Nb, As, and Zr exhibited the strongest correlations with U distribution among solid-phase components. This study indicates a significant spatial variation of U distribution in the shooting range site. Fe/Mn oxides and carbonate were the major solid-phase components for binding U in the weapon test site.

Cool OtOprotective Ear Lumen (COOL) Therapy for Cisplatin-induced Hearing Loss.

HYPOTHESIS: Localized cooling of the external ear has a protective effect on the susceptibility to cisplatin-induced hearing loss. BACKGROUND: We previously demonstrated significant protection from cisplatin-induced hearing loss using cool water ear canal irrigation. However, the study was limited to a single bolus injection of cisplatin and an acute time period. Here, we examined the application of localized cooling of the ear canal with repeated doses of cisplatin, over an expanded period of time, and using two methods of cooling. METHODS: Twenty-four guinea pigs (12 male and 12 female) underwent auditory physiological testing (auditory brainstem response and distortion product otoacoustic emissions at 8-32 kHz) and pre/postadministration of cisplatin. Cisplatin (4 mg/kg i.p.) was administered in 3 weekly single injections for a total of 12 mg/kg. While anesthetized, the left ears of the guinea pigs were exposed to either cool water (22°C; ICS Water Caloric Irrigator), a cool ear bar (15°C, cooled by a Peltier device; TNM, Scion NeuroStim), or left uncooled as a sham control. The animals were tested 3 days post each dosage and 1 month post the final dose. At the end of the experiment the animals were euthanized for histological evaluation. RESULTS: We found that hearing loss was significantly reduced, and hair cell survival greatly improved, in animals that received cooling treatments compared to cisplatin-only control animals. No significant difference was observed between the two methods of cooling. CONCLUSION: Localized cooling of the ear canal during administration of cisplatin mitigated loss of auditory function and loss of hair cells.